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Objective. Endometrial cancers have historically been classified by histomorphologic appearance, which is subject to interobserver
disagreement. As molecular and biomarker testing has become increasingly available, the prognostic significance and accuracy of
histomorphologic diagnoses have been questioned. To address these issues for a large, prospective cohort study, we provide the
results of a centralized pathology review and biomarker analysis of all incidental endometrial carcinomas occurring between
1976 and 2012 in the Nurses’ Health Study. Methods. Routine histology of all (n = 360) cases was reviewed for histomorphologic
diagnosis. Cases were subsequently planted in a tissue microarray to explore expression of a variety of biomarkers (e.g., ER, PR,
p53, PTEN, PAX2, AMACR, HNF1β, Napsin A, p16, PAX8, and GATA3). Results. Histologic subtypes included endometrioid
(87.2%), serous (5.6%), carcinosarcoma (3.9%), clear cell (1.7%), and mixed type (1.7%). Biomarker results within histologic
subtypes were consistent with existing literature: abnormal p53 was frequent in serous cases (74%), and HNF1β (67%), Napsin
A (67%), and AMACR (83%) expression was frequent in clear cell carcinomas. Our dataset also allowed for examination of
biomarker expression across non-preselected histologies. The results demonstrated that (1) HNF1β was not specific for clear cell
carcinoma, (2) TP53 mutations occurred across many histologies, and (3) GATA3 was expressed across multiple histotypes,
with 75% of positive cases demonstrating high-grade features. Conclusions. Our findings establish the subtypes of endometrial
cancer occurring in the Nurses’ Health Study, corroborate the sensitivity of certain well-established biomarkers, and call into
question previously identified associations between certain biomarkers (e.g., HNF1B) and particular histotypes.
1. Introduction
Endometrial cancers have historically been subclassified by
their histomorphologic appearance alone [1, 2]. However,
histomorphologic classification suffers from interobserver
agreement issues, particularly in the case of high-grade
endometrial carcinomas (e.g., FIGO grade 3 endometrioid,
clear cell carcinoma, serous carcinoma, and carcinosarcoma)
[3–7]. Further, in the molecular era, morphologic subtyping
is considered insufficient for determining prognosis. Most
famously, The Cancer Genome Atlas molecularly classified
endometrial tumors into four categories which were prog-
nostically significant irrespective of histomorphology [8].
Despite the inherent limitations in morphologic analysis
of tumors, histomorphologic diagnosis largely determines
inclusion in cancer registries as well as in clinical and
epidemiologic research [9]. These diagnoses may suffer from
changes in diagnostic categories over time, an absence of
centralized pathology review, and, importantly, the absence
of corroborative biomarker (immunohistochemical) data.
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The application of biomarkers (i.e., immunohistochemi-
cal staining) assists pathologists in rendering more accurate
diagnoses. A recent study found that up to 40% of cases ini-
tially diagnosed as high-grade endometrial endometrioid
adenocarcinomas may be reclassified as uterine serous carci-
nomas based on a panel of four immunostains (p53, p16,
estrogen receptor (ER), and mammaglobin) [10]. Immunos-
tains in routine practice, however, are often not pursued due
to a pathologist’s degree of morphologic certainty or the
possibility of ambiguous results.
Further, biomarkers have their own limitations. Bio-
marker sensitivity and specificity have largely been deter-
mined by research conducted on highly selected cohorts of
tumors, typically including only those with unambiguous
morphologies. Thus, the sensitivity and specificity of markers
tends to shift once the markers are applied in the clinical
setting and to cases with less prototypical morphologies. For
example, hepatocyte nuclear factor-1beta (HNF1β) expression
was initially thought to have a specificity of 93 to 100% for
clear cell carcinoma [11–14]; however, overtime, the specific-
ity has been questioned as expression has been documented
in a subset of serous and endometrioid carcinomas [15–17].
In this study, we attempt to address two of the aforemen-
tioned issues. First, we perform a centralized review of the
incidental endometrial cancer cases arising in the Nurses’
Health Study, a large, prospective cohort study with long-
term follow-up. Secondly, we attempt to systematically apply
a set of biomarkers to incidental endometrial cancer cases,
thus exploring expression across a spectrum of subtypes.
We explore biomarkers that are currently well-established
in their interpretation (e.g., p53) as well as more novel bio-
markers (e.g., GATA3). Further, we explore the limitations
and benefits of applying biomarkers retrospectively in the
case of a large epidemiologic study, especially the feasibility
of interpretation in the setting of tissue microarrays.
2. Materials and Methods
This study was approved by the Human Studies Review
Board at Brigham and Women’s Hospital. The protocol for
this study was approved by the Human Research Committees
at Brigham and Women’s Hospital, Boston, MA, USA.
2.1. Case Selection. Using data from the Nurses’Health Study
[18, 19], a prospective cohort of 121,700 female nurses initi-
ated in 1976, all incidental endometrial cancers diagnosed
between 1976 and 2012 were identified.
When available, paraffin-embedded tissue and hematoxy-
lin and eosin stained slides from the patient’s endometrial
biopsy or hysterectomy were obtained. Only cases with
paraffin blocks for the creation of tissue microarrays were
included. Full hematoxylin and eosin sections of the original
clinical diagnostic blocks underwent central pathology review
by a pathologist (GM), and a histologic diagnosis was ren-
dered for each case using current diagnostic criteria [1]. Addi-
tional information regarding case ascertainment and tissue
microarray construction has been published elsewhere [20].
For each specimen, a representative paraffin-embedded
tissue block was chosen, and three 0.6mm cores were planted
in a tissue microarray. Serial sections of each microarray were
used for marker studies as below.
2.2. Immunohistochemical Studies. For each marker studied,
four-micron thick sections of each tissue microarray were
stained in the following sequence: hematoxylin and eosin,
marker replicate 1, pankeratin AE1/AE3 (Dako Cat#M3515
at 1 : 200 dilution), and marker replicate 2. The following
immunostains were performed using the Leica Bond III
staining platform using the following primary antibodies:
estrogen receptor (ER, murine monoclonal ERID5 (Dako)
at 1 : 300 dilution), progesterone receptor (PR, murine
monoclonal PgR636 (Dako) at 1 : 150 dilution), p53 (murine
monoclonal PAb 1801 (Leica Biosystems) at 1 : 300 dilution),
AMACR (rabbit monoclonal Z2001 (Zeta Corp) at 1 : 50),
ARID1A (rabbit polyclonal HPA005456 (Sigma) at 1 : 200
dilution), GATA3 (murine monoclonal L50-823 (Biocare)
at 1 : 100 dilution), HNF1β (rabbit polyclonal HPA002083
(Sigma) at 1 : 500 dilution), Napsin A (murine monoclonal
NCL-L-Napsin A (Leica) at 1 : 400 dilution), p16 (murine
monoclonal E6H4 (Ventana) at 1 : 300 dilution), PAX2
(polyclonal rabbit Z-RX2 (InVitrogen) at 1 : 300 dilution),
PAX8 (rabbit polyclonal 10336-1-AP (Proteintech) at
1 : 600 dilution), and PTEN (murine monoclonal 6h2.1
(Millipore) at 1 : 100).
2.3. Marker Interpretation. All stained slides were digitally
captured at 40x magnification by a Hamamatsu nanozoomer
whole slide digital scanner. For each marker, hematoxylin
and eosin and keratin-stained images of matched tissue
microarray sections were used to confirm the presence of
tumor tissue and to discriminate tumor cells from back-
ground as needed. Duplicate stains for each marker were
independently scored for marker specific signal within tumor
cells (JW and GM) (see Table 1 for scoring methodology).
Discordant replicates were resolved by rereview. Markers
scored on continuous scales were averaged across the dupli-
cate runs for final data analysis. Technical failures due to
tissue dropout, high background, or low signal were excluded
as noninformative on a marker-by-marker basis.
Due to the limited tumor represented on the tissue
microarrays, p53 was only interpreted as abnormal when
staining was diffuse and strong; a “null” phenotype was not
reported due to the possibility of failed staining or regional
variability in tumor expression and thus the possibility of
false positives [21].
2.4. Case Inclusion and Exclusion Criteria. Some patients had
separate endometrial biopsies and hysterectomy specimens
containing tumor. After staining, only unique specimens
(1 per patient) were included in the final analysis, with
preference for hysterectomy specimens over biopsies.
Nonepithelial tumors were excluded. Carcinosarcoma and
mixed carcinoma cases were included.
2.5. Covariates. Age at diagnosis (continuous) and body mass
index at diagnosis [22] (continuous, kg/m2) were assessed
from the last biennial Nurses’ Health Study questionnaire
prior to cancer diagnosis.
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2.6. Statistical Analyses. Statistical analysis was performed in
SYSTAT (v13.1, Systat Software, Inc., San Jose, CA). One-
way ANOVA was used to independently compare age and
body mass index with the diagnostic tumor subtypes. t-tests,
with separate variances, were employed to compare bio-
marker expression across age and body mass index. Results
with a p value < 0.05 were considered statistically significant.
Hierarchical clustering of bimodally scored (normal vs.
abnormal) marker results was performed using Ward’s link-
ages and Jaccard similarity coefficient distance metric.
Bimodal scoring of the continuous percentages of estrogen
and progesterone receptor was done across a 10% threshold.
3. Results
Pathology materials were received for 472 patients with
reported endometrial cancer. After application of the inclu-
sion criteria, 360 patients had adequate tissue for inclusion
in the tissue microarray (343 hysterectomy specimens and
17 biopsy/curettages).
3.1. Histomorphologic Review. Histomorphologic diagnoses
were as follows: 314 endometrioid (87.2%), 20 serous
(5.6%), 14 carcinosarcoma (3.9%), 6 clear cell (1.7%), and 6
mixed endometrioid plus nonendometrioid type (1.7%).
Within the endometrioid group, 244 were grade 1, 43 were
grade 2, and 27 were grade 3.
3.2. Biomarker Results within Histomorphologic Diagnoses
(Table 2). Clear cell carcinomas frequently expressed
AMACR, HNF1B, and Napsin A (83.3%, 66.7%, and 66.7%,
respectively). Serous carcinomas commonly displayed dif-
fuse, strong p53 staining (mutant phenotype; 73.7%) and
p16 diffuse positivity (70%). Endometrioid tumors demon-
strated high rates of ER (92.7%) and PR (85.1%) expression,
with the highest ER and PR expression noted in FIGO grade
1 endometrioid tumors.
3.3. Biomarker Expression across Histomorphologic Diagnoses.
GATA3 was expressed across histotypes (16 cases total; 10
endometrioid (62.5%), 3 serous (18.8%), 2 carcinosarcoma
(12.5%), and 1 clear cell (6.25%)). GATA3 expression corre-
lated positively with expression of HNF1β (p = 0:009) and
p16 (p = 0:017) and absence of staining for PAX2 (p = 0:002),
ER (p < 0:001), and PR (p < 0:001). Rereview of the GATA3
positive tumors revealed an absence of morphologic findings
consistent with mesonephric carcinomas. Further, 12 of the
16 cases showed high-grade morphology with ambiguous
cytology (Figure 1). GATA3 and PAX8, respectively, markers
of mesonephric and Müllerian origin, were not always mutu-
ally exclusive. 79.6% of cases (262/329) were positive for only
one of the two markers, 15.8% (52/329) were negative for both,
and 4.6% of cases (15/329) were positive for both.
Diffuse, strong p53 expression (mutant phenotype) was
seen across histotypes. Of p53 mutant tumors (37 total),
37.8% were serous, 32.4% were endometrioid, 13.5% were
carcinosarcoma, 8.1% were clear cell carcinoma, and 8.1%
were mixed type. HNF1β showed similar lack of correlation
with a specific histologic type with 71.9% of positive cases
being endometrioid, 10.5% serous, 7.0% carcinosarcoma,
7.0% clear cell carcinoma, and 3.5% mixed type. Stated
another way, 33.3% of carcinosarcomas, 66.7% of clear cell
carcinomas, 13.7% of endometrioid carcinomas, 40% of
mixed type tumors, and 31.6% of serous carcinomas stained
positively for HNF1β.
Mutant p53 staining had variable correlation with aber-
rant p16 staining, a previously reported association especially
in serous cancers [23]. In our overall cohort, p53 and p16
stainings were discordant in 8.9% of cases (31/347). Of these
cases, 48.3% (15/31) demonstrated mutant p53 with only
patchy p16 staining.
3.4. Marker Expression Patterns. Hierarchical clustering of
biomarker results from 240 cases with complete data shows
Table 1: Biomarker scoring and rationale for inclusion.
Marker Rationale #scoring
AMACAR Candidate clear cell type marker 0 =WT (neg), 1 = pos, 3 = NI
ARID1A Candidate clear cell type marker 0 =WT (pos), 1 = lost (neg), 3 = NI
Hnf1beta Candidate clear cell type marker 0 =WT (neg), 1 = pos, 3 = NI
Napsin A Candidate clear cell type marker 0 =WT (neg), 1 = pos, 3 = NI
p16 Candidate serous type marker 0 =WT (neg or patchy), 1 = diffusely pos, 3 = NI
ER Hormone responsiveness
Percentage positive nuclear staining: 0 = neg (<10% staining),
1 = pos (≥10% staining); also
PR Hormone responsiveness
Percentage positive nuclear staining: 0 = neg (<10% staining),
1 = pos (≥10% staining)
PAX8 Müllerian (paramesonephric) lineage marker 0 = neg, 1 = pos, 3 = NI
PAX2 Primary inactivation mechanism 0 =WT (pos), 1 = lost (neg), 3 = NI
p53 Primary mutation mechanism 0 =WT, 1 = diffuse, strong (mutated) expression 3 = NI
PTEN Primary mutation mechanism 0 =WT (pos), 1 = lost (neg), 3 = NI
GATA3 Wolffian (mesonephric) lineage marker 0 =WT (neg), 1 = pos, 3 = NI
#WT=wild type; NI = not informative; pos = positive; neg = negative.
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two main clades corresponding to PTEN and P53 mutant
classes (Figure 2).
3.5. Age, Body Mass Index, and Biomarker Expression. Age at
diagnosis was found to be statistically different across
histologic categories (p = 0:02, Table 3), with endometrioid
type tumors presenting on average at a younger age
(mean = 68:5 y) than other subtypes. Body mass index did
not differ significantly across diagnostic categories (p = 0:1,
Table 3).
When body mass index and age were compared with
biomarker expression (Table 4), several significant associa-
tions were found. Body mass index was significantly lower
in women whose tumors expressed HNF1β (26.9 vs.
30.5 kg/m2, p < 0:001), Napsin A (25.1 vs. 30.0 kg/m2, p =
0:007), and mutant p53 (26.0 vs. 30.3 kg/m2, p < 0:001). Body
mass index was significantly higher in women whose tumors
expressed ER (30.3 vs. 27.2 kg/m2, p = 0:001) and PR (30.4
vs. 28.2 kg/m2, p = 0:033). The loss of expression of PAX2
was associated with younger age at diagnosis (68.6 vs.
70.5, p = 0:035).
4. Discussion
Our study addresses two key issues. First, we performed a
centralized review of the incidental endometrial cancers in
the Nurses’ Health Study. Secondly, through the administra-
tion of biomarkers to a large, incidental cohort, we explored
biomarker expression across a spectrum of endometrial
tumors with variable morphologies.
As was expected, most incidental cases of endometrial
cancer in the Nurses’ Health Study (87.2% of cases) were
“type 1 endometrial carcinomas” (i.e., endometrioid adeno-
carcinomas arising secondary to estrogen stimulation). Such
“type 1” cancers account for the majority of endometrial
tumors and typically arise in obese, post-menopausal women
[24–26]. “Type II endometrial carcinomas” (i.e., predomi-
nantly nonendometrioid carcinomas arising in the setting
of TP53mutation or 1p deletion) [25–27], were less common
in our cohort, reflecting their lower prevalence in the general
population.
Our biomarker exploration of these tumors confirmed
the preexisting associations between type I and type II endo-
metrial carcinomas with hormonal receptors and p53 expres-
sion. Low-grade endometrioid carcinomas (type I) expressed
high rates of ER and PR, supporting the hormonal pathway
to carcinogenesis. Likewise, our type 2 tumors (nonendome-
trioid) demonstrated frequent p53 overexpression (mutant
phenotype). Such findings are not novel, but do support the
feasibility and reliability of applying biomarkers to large
epidemiologic studies in a retrospective fashion.
While we confirmed preexisting biomarker expression
pattern within histotypes, the advantage of our study was
the ability to assess biomarkers across an incidental cohort
of histomorphologic subtypes. Multiple marker-histotype
correlations were found to be less specific than previously
thought. Specifically, while p53 abnormalities are seen in
Table 2: Biomarker expression by histotype.
(a) Reportable marker results in 360 tumors studied
Immunomarker, scored results
AMACR ARID1A HNF1B ER GATA3 Napsin A P16 P53 PAX2 PAX8 PR PTEN
POS NEG POS >10% POS POS POS Mutant NEG POS >10% NEG
Total cases stained 360 360 360 360 360 360 360 360 360 360 360 360
Total excluded 19 23 19 12 20 16 10 4 13 24 16 52
Total # informative 341 337 341 348 340 344 350 356 347 336 344 308
Total # abnormal 48 115 57 300 16 6 37 37 253 282 264 124
% abnormal 14.1 34.1 16.7 86.2 4.7 1.7 10.6 10.4 72.9 83.9 76.7 40.3
(b) Distribution of reportable marker results, by tumor histotype
Histotype
Immunomarker scored results, informative cases % (n/total)
AMACR ARID1A HNF1β ER GATA3
Napsin
A































































































































∗Percentages are calculated for each marker (columns) by histotype (rows). Scorable results only, noninformative cases excluded.
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73.7% of serous cancers, 62.2% of all p53 abnormal cancers
had a nonserous histology. This experience is mirrored in
other purely marker-driven endometrial cancer classification
systems such as the genomic-based TCGA classification
schema, where molecular and histopathologic classes only
partly overlap, and some unique molecular phenotypes of
clinical interest (such as polymerase E mutation) cannot be





Figure 1: Four examples ((a–d), each a separate case) of GATA3-positive tumors with nonmesonephric histology. (a) Serous. (b) Ambiguous
morphology, most consistent with grade 3 endometrioid carcinoma. (c) Conventional grade 1 endometrioid. (d) Carcinosarcoma.
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Our study additionally contributes to the growing evi-
dence that HNF1β is a nonspecific marker [15–17]. While
two-thirds of our clear-cell cases stained with HNF1β,
31.6% of serous carcinomas and 13.7% of endometrioid car-
cinomas expressed HNF1β, making HNF1β staining an
unreliable marker in the clear cell versus serous/endome-
trioid differential. Thus, we conclude that HNF1β, on its
own, should not be considered a specific marker for clear cell
carcinoma in clinical practice.
Our findings regarding expression of GATA3 are also of
interest. Prior studies demonstrate GATA3 be a highly sensi-
tive and specific marker for mesonephric lineage in lesions of
the lower female genital tract [28, 29]. In our study, GATA3
positive staining in an unselected sample of uterine tumors
did not correspond well to any single histotype. Notably,
none of the cases, even those of low-grade cytology, displayed
the classic morphologic features of mesonephric carcinomas
(e.g., small round tubules, cuboidal or flatted epithelium, and
angulated vesicular nuclei). Furthermore, 12 of 16 positive
cases displayed high-grade or ambiguous cytologic features,
raising the possibility that poorly differentiated endometrial
tumors may express GATA3 not due to lineage but rather
due to gain of function mutations. This is further demon-
strated by our finding that 4.6% of cases demonstrated posi-
tivity for both PAX8 and GATA3, two stains that should be
mutually exclusive of each other.
An unsupervised self-organizing dendrogram of marker
results in our tumors gives an indication of how combinato-
rial marker trends can define tumor subgroups (Figure 2).
Two major clusters are evident: a p53 mutant arm and a
PTEN/PAX2 arm, corresponding to “type II” and “type I”
endometrial cancers, respectively. Further, there is a
p16/p53 subgroup distinct from a Napsin A/AMACR/
HNF1β class. Of note, GATA3 expression clustered with
both clear cell markers and/or p53/p16 expression. This clus-
tering provides additional evidence that GATA3 expression
likely denotes aberrant expression/gain of function muta-
tions in high-grade malignancies arising from mutations in
TP53 rather than mesonephric lineage.
Given our unique dataset, we were able to compare bio-
marker expression across participants’ ages and body mass
index. As expected, p53 expression was associated with sig-
nificantly lower body mass index, and ER/PR expression
was associated with significantly higher body mass index
(additional ER/PR findings in this cohort are reported else-
where [20]). Additionally, endometrioid-type tumors tended
to present at earlier ages than other subtypes. These findings
are consistent with commonmechanisms of endometrial car-
cinogenesis in which either hormonal stimulation (typically
in the setting of obesity) [30] or p53 mutation leads to neo-
plastic growth [25, 26, 31, 32].
Our study did highlight some of the necessities and limi-
tations of working with tissue microarrays. Of note, when
performing a centralized pathology review, we found it
essential to render a morphologic diagnosis on whole H&E
slides only, not on the tissue microarray preparations. This
is due to the limited amount of tumor present on the tissue
microarray. Secondly, due to the occasional absence of inter-
nal controls noted in the tissue microarray tissues, we recom-
mend running separate positive controls on each tissue
microarray assay. We also recommend replicate stain reads
to control for idiosyncratic runs, ideally with the replicates
reviewed independently by mutually blinded pathologists.
The main limitation of using tissue microarrays in our study
was the inability to reliably interpret p53 protein null pheno-
types caused by rare nonsense mutations [33]. Thus, more of
our cases likely had aberrant p53 staining than we could reli-
ably conclude from our tissue microarray preparations.
In this study, we provide a centralized review of the inci-
dental endometrial cancers in the Nurses’ Health Study as
well as the biomarker expression results across this cohort.
This data is largely applicable to future clinical/epidemiologic
studies that derive data on endometrial cancers form the
Nurses’ Health Study. However, we were also able to test
the hypothesis that biomarker studies in which cases are
preselected by pathologists likely lead to overestimated sensi-
tivities and specificities. In the case of GATA3, p53, and















Figure 2: Self-organized hierarchical clustering of 12 biomarkers in
274 endometrial cancers. Dendrogram shows degree of marker
association (distance measure) in 274 cases with complete data for
all markers (cases with partial missing data excluded for
computational reasons). Estrogen (ER) and progesterone (PR)
receptor results scored dichotomously across a 10% threshold.
Two major clusters are evident, containing P53 and PTEN,
respectively. Ward’s linkage method and Jaccard similarity
coefficient distance metric for binary data. Distal branches, such as
those containing ER + PR and p16 + p53, indicate a level of
association between members of the limb.
Table 3: Mean age and body mass index at presentation by tumor
histotype.




Clear cell carcinoma 71.4 25.2
Mixed type 69.8 28.6
p (Kruskal-Wallace) 0.11 0.115
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HNF1β, we found this hypothesis to be true. We believe our
approach of testing biomarkers across an incidental popula-
tion of cancers gives a more realistic sense of the utility of
such markers when applied to incidental disease. Further,
our findings mimic those of The Cancer Genome Atlas and
other data collected from next-generation sequencing in
which there is much overlap in the mutational profiles of
tumor categories as defined by histomorphology. We con-
clude that expression of a single biomarker (e.g., HNF1β
and GATA3) should not be interpreted as diagnostic of a
particular tumor type without taking into consideration the
histology. We would recommend that, when in doubt of the
histology, a panel of immunostains, including stains redun-
dant for a diagnosis (e.g., PTEN, ARID1a, and ER for endo-
metrioid adenocarcinoma; HNF1β, Napsin A, and AMACR
for clear cell carcinoma; and p16 and p53 for serous carci-
noma), be performed rather than relying on a single immu-
nostain. Lastly, we show that tissue microarrays have some
limitations; however, the results of biomarker studies in this
setting are largely reliable and reproducible.
Data Availability
The Nurses’ Health Study data are housed within the
Harvard School of Public Health and are not publicly avail-
able without an IRB and application for access.
Additional Points
Highlights. (1) This study characterizes all incidental endo-
metrial cancers in the Nurses’Health Study. (2) Our findings
call into question specificity of several commonly used bio-
markers. (3) We demonstrate that tissue microarrays are
reliable and reproducible in retrospective studies.
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